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Abstract: Aquaculture industries, and in particular the farming of fish and crustaceans, are major
contributors to the economy of many countries and an increasingly important component in global
food supply. However, the severe impact of aquatic microbial diseases on production performance
remains a challenge to these industries. This article considers the potential applications of microalgal
technology in the control of such diseases. At the simplest level, microalgae offer health-promoting
benefits as a nutritional supplement in feed meal because of their digestibility and high content
of proteins, lipids and essential nutrients. Furthermore, some microalgal species possess natural
anti-microbial compounds or contain biomolecules that can serve as immunostimulants. In addition,
emerging genetic engineering technologies in microalgae offer the possibility of producing ‘functional
feed additives’ in which novel and specific bioactives, such as fish growth hormones, anti-bacterials,
subunit vaccines, and virus-targeted interfering RNAs, are components of the algal supplement.
The evaluation of such technologies for farm applications is an important step in the future
development of sustainable aquaculture.
Keywords: aquaculture; chloroplast transformation; disease control; microalgae; nuclear transformation;
vaccine
1. Introduction
According to a 2016 report by the Food and Agriculture Organization of the United Nations (FAO),
aquaculture marine food production has dramatically increased in the years since 1994, while capture
fishery yields have remained relatively unchanged [1]. During this time, the aquaculture industry
has become an important contributor to the national economies of many countries, in particular
China, Mexico, and South-East Asian (SEA) countries. World aquaculture production in 2014 was
valued up to US$160.2 billion, of which US$99.2 billion were from finfish, US$19 billion from molluscs,
US$36.2 billion from crustaceans, and US$3.7 billion from other aquatic animals including amphibians.
However, this important industry is constantly threatened by the possibility of widespread infection of
the intensively farmed animals, which can result in dramatic losses [2]. For example, the major diseases
causing high losses in shrimp stocks are from viral pathogens (the White Spot Syndrome Disease
(WSSD) and the Yellow Head Disease (YHD)) and from bacterial pathogens (the Early Mortality
Syndrome (EMS)) [3,4]. Diseases in fish are mostly caused by bacterial pathogens, the most prevalent
of which are species of Aeromonas, Pseudomonas, and Vibrio [5]. More recently, a number of viral groups
have also been reported as causative agents of disease in fish, including Betanodavirus such as nervous
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necrosis virus (NNV), Megalocyticvirus such as infectious spleen and kidney necrosis virus (ISKNV),
and red sea bream iridovirus (RSIV) [6,7]. There is therefore a pressing need to find effective strategies
to address these continuous and unpredictable diseases.
The management of infection using antibiotics or other chemotherapeutic agents that target
bacterial pathogens and eukaryotic parasites is widespread within the aquaculture industry [8].
However, such a strategy does not afford protection against viral diseases, is potentially harmful to
the environment, raises concerns regarding antibiotic contamination of the product, and encourages
the emergence and spread of drug resistance amongst pathogens and parasites [9,10]. A better and
safer strategy for disease control is vaccination, and a number of vaccines have been shown to be
highly effective against specific viral or bacterial pathogens of fish [11]. Nevertheless, there are
economic, technical, and regulatory challenges associated with vaccination. The cost of production
and ‘cold-chain’ storage of vaccines (whether these are live-attenuated or killed whole microorganisms,
recombinant subunit vaccines, or DNA vaccines) is often significantly higher than the production
costs for antibiotics. The effective delivery of a vaccine dose to each animal also presents a challenge.
Whilst intra-parenteral or intra-muscular delivery by injection minimizes vaccine wastage and ensures
effective administration of a known amount, the process of capturing, handling, anesthetizing,
and injecting the fish is very labor-intensive and costly and can cause injury to the fish. Furthermore,
it is not feasible for small, juvenile fish or for crustaceans and impractical when repeat vaccinations are
required. An alternative method involves immersion in a suspension of the vaccine using a bath, dip,
or spray, but this can also be stressful to the fish and expensive in terms of amount of vaccine required.
The simplest and most sought after method is oral delivery of the vaccine by formulating it
into the aquaculture feed. This approach allows mass vaccination of fish of all sizes, is non-stressful,
requires little technical skill by the operator, and allows repeat dosing [11,12]. The key drawback
of oral vaccination is the uncertainly and efficacy of a delivered dose, given that the vaccine can be
lost through degradation—both in the water prior to feeding and in the fish gut through digestion
prior to uptake by the immune tissue in the lower intestinal tract. As a consequence, oral vaccination
often results in only a limited duration of immunity and may necessitate repeat dosing. Furthermore,
variation in feeding between individual animals results in a Poisson distribution of the received dose.
All of these factors mean that significantly more vaccine is required than for injection, and robust
methods for DNA or antigen encapsulation are needed to allow efficient delivery to the immune
tissue [13].
2. The Application of Microalgae in Aquaculture
Microalgae are a natural food source for many small aquaculture animals including larval
shrimp and fish fry, and several microalgal species are used commercially as live prey or as dried
whole algal feed [14]. The most frequently used species are those of Chlorella, Tetraselmis, Isochrysis,
Pavlova, Phaeodactylum, Chaetoceros, Nannochloropsis, Skeletonema, and Thalassiosira, with a combination
of different species often employed to provide the right balance of protein, lipids, and essential
micronutrients [15]. In older animals, the supplement of fishmeal-based or grain-based feed with
algal-derived biomass contributes additional nutritional value and also supplies necessary pigments
such as the red astaxanthin that colours the flesh of salmonids and shellfish [15]. In addition to the
inherent nutritional benefits, algal supplements have been reported to contain various compounds
that serve as non-specific immunostimulants, improving the innate defense mechanisms in the animal
and thereby providing enhanced resistance to pathogens [15]. Finally, many microalgal species have
been reported to produce anti-microbial compounds that might be effective against particular bacterial,
viral, and protist pathogens [16]. Microalgae, therefore, represent a beneficial component of finfish
and shellfish feed, with these phototrophic microorganisms cultured in low-cost photobioreactors,
either on-site (to provide live algae as a ‘green water’ supply) or off-site at a more appropriate location
for algal cultivation (producing dried algae, frozen algal concentrates, or algal pastes suitable for
storage and shipping). Moreover, the development of genetic engineering technologies for many algal
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species [17,18] offers the possibility of ‘functionalising’ the algal feed by engineering the algal cell
to produce a novel bioactive, such as a vaccine, growth hormone, or anti-microbial agent. The cell
then serves as a natural bio-encapsulation device for oral delivery of the bioactive to the target tissue.
Of particular significance in this regard is the development of chloroplast engineering for several
species. This offers both the possibility of high-level and stable accumulation of transgenic products in
the organelle, but also an additional layer of bio-encapsulation provided by the multiple chloroplast
membranes [19].
This review, therefore, focuses on the use of both natural and transgenic microalgal species as feed
to control aquaculture diseases particularly in shrimp and fish, since these contribute a large proportion
of total aquaculture production. The integration of microalgae into aquaculture is summarized in
Figure 1.
Figure 1. Overview of the current strategies for microalgal exploitation in aquaculture.
3. Microalgae as a Health-Promoting Supplement for Coping with Aquaculture Disease
Bacteria are a major cause of aquatic animal diseases, and the number of antibiotic-resistant
bacterial pathogens is continuously increasing. Various microalgal species exhibit natural anti-bacterial
activities, and some also contain biomolecules that serve as immunostimulants [15,16]. Consequently,
both crude algal extracts and whole cells have been used as a replacement or as a supplement
in shrimp or fish feed to help address the issue of bacterial infections [20,21]. Members of the
Vibrio bacterial genus are most often used as a target pathogen to test the inhibitory effect of microalgae.
For example, a microalgal homogenate from Tetraselmis suecica showed good antibacterial activity
in vitro against several Vibrio species including significant shrimp pathogens such as Vibrio alginolyticus,
Vibrio anguillarum, Vibrio parahaemolyticus, and Vibrio vulnificus [22]. This study revealed a marked
decrease in bacterial mobility with elongation and vacuolisation of the cells, which resulted in
an inhibition of bacterial growth. Other microalgal species commonly used as aquaculture feed
have similarly shown antibacterial activity in vitro against particular shrimp and fish pathogens.
These algae include Chaetoceros lauderi, Dunaliella tertiolecta, Euglena viridis, Phaeodactylum tricornutum
and Stichochrysis immobilis [16,23,24]. Natrah et al. (2011) reported that extracts from several marine
and freshwater algae were able to interfere with quorum sensing mediated by the small molecule
acyl-homoserine lactone in test bacteria including the pathogen Vibrio harveyi. This is significant,
since quorum sensing is a mechanism of cell-to-cell communication that plays a key role in bacterial
virulence [25]. Furthermore, several studies have shown that algal-derived long-chain polyunsaturated
fatty acids (LC-PUFAs) such as eicosapentaenoic acid (EPA), as well as algal sterols, have anti-bacterial
properties and can be effective against both Gram-positive and Gram-negative bacteria [26,27].
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Therefore, inclusion of microalgae in the diet of aquatic animals is likely to contribute to a reduced risk
of bacterial infection.
Microalgal feeding also appears to improve disease tolerance of the host animal. Replacement
of fish oil with algal meal containing high amounts of the LC-PUFAs docosahexaenoic acid (DHA)
and arachidonic acid (AA), significantly improved immune parameters such as total haemocyte count,
phenoloxidase activity, superoxide dismutase activity, and bactericidal activity in the post-larval
stage of the Pacific white shrimp (Litopenaeus vannamei), resulting in improved survival rates against
V. harveyi infection [28]. Our own unpublished studies into immunity induction following replacement
of either fish meal or fish oil with microalgae revealed a proportion-dependent effect in agreement with
Nonwachai et al. [28]. The carotenoid pigments lutein, zeaxanthin, and astaxanthin that are abundant
in microalgae were also reported to increase the survival of shrimp and fish, as well as of other
crustaceans, when subjected to disease infection [29,30]. Vitamin C, which is found in high amounts in
several microalgal species, was reported to boost immunity in shrimp resulting in decreased mortality
from Vibrio species [31,32]. Radhakrishnan et al. found that post larvae of the giant freshwater prawn
Macrobrachium rosenbergii had significantly higher vitamin C levels following a feed diet containing
cyanobacteria (Spirulina platensis), green alga (Chlorella vulgaris), and fern (Azolla pinnata) [33]. However,
there have been no studies confirming a relationship between higher antioxidant levels as a result
of microalgal feeding and disease tolerance. Nevertheless, several studies have reported the use
of a feed diet containing microalgae to combat bacterial pathogen in aquaculture and attributed
this to a combination of antibacterial activity and host immunity induction by microalgal-derived
compounds [34–36].
Immunostimulants also play a significant role in terms of enhancing the protection against viral
pathogens [36,37]. Feed diets supplemented with 80 mg/kg astaxanthin, present in high amounts in
several green algal species such as Haematococcus pluvialis and usually used for improving coloration,
conferred partial white spot syndrome virus (WSSV) protection and immunity and antioxidant enzyme
induction in L. vannamei [38]. Similarly, Dunaliella salina was found most applicable for viral protection,
in particular against WSSV, since this species contains high amounts of beta-carotene. A feed diet
containing beta-carotene from D. salina at 15 mg/kg for six weeks had no significant effect on haemocyte
count and phenoloxidase activity in black tiger shrimp (Penaeus monodon). However, a WSSV challenge
test revealed a two–three-fold higher protection efficiency compared to normal feed [39]. P. monodon
fed a diet supplemented with dry D. salina showed higher levels of prophenoloxidase than when
fed a diet without D. salina and short-term induction of antioxidant substances such as superoxide
dismutase and catalase. While P. monodon challenged with WSSV and fed a diet without D. salina
showed 100% mortality within 48 h, an experimental group receiving a D. salina-containing diet showed
a 60% survival on day 5 and, 100% mortality was delayed until day 10 [40]. Despite these promising
results with crustaceans, we have not found any similar studies reporting the use of microalgae as feed
for improved viral protection in fish.
4. Engineering Microalgae to Produce Novel Antiviral and Antibacterial Biomolecules
Recent advances in the genetic engineering of a wide range of microalgal species [17,18] are
now making possible the development of bespoke strains for oral delivery of novel anti-microbial
agents, as well as of other beneficial recombinant molecules, including growth promoters and dietary
enzymes such as phytases and cellulases [41,42]. For some species—in particular, the green alga
Chlamydomonas reinhardtii—advanced synthetic biology methods are being developed for engineering
both the nucleus and the chloroplast genomes [43,44]. Successful introduction of a functional transgene
into a cell involves three requirements. The first is the physical delivery of the foreign DNA into
the nuclear or chloroplast genome (i.e., ‘transformation’). In the case of microalgae, the small cell
size and thick cell wall often present significant transformation challenges. However, techniques
such as microparticle bombardment, electroporation, agitation with glass beads or silicon carbide
whiskers, or Agrobacterium-mediated DNA transfer, have all been exploited to address these challenges
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in different species [18,41]. Furthermore, the use of cell wall-deficient mutants or of algae at a natural
stage in their life cycle characterized by a minimal cell wall has facilitated DNA delivery [45,46].
Integration of the DNA into the chloroplast genome can be directed to a specific locus via a process of
homologous recombination, whereas integration into the nucleus of most algal species is uncontrolled,
occurring essentially at random loci [18]. However, the ongoing development of genome targeting
technologies for microalgae based on CRISPR-Cas, should allow precise and predictive insertion of
transgenes into chosen loci in the nucleus [47]. This will avoid the issue of ‘position effects’ whereby
the site of insertion can have a profound influence on the level and stability of transgene expression.
The second requirement is the selection for the rare transformant lines within a large population of
untransformed cells. Typically, selectable markers based on bacterial antibiotic-resistance genes have
been used for both nuclear transformation (e.g., zeomycin or kanamycin resistance) or chloroplast
transformation (e.g., spectinomycin or erythromycin resistance) [18]. However, the dispersal of algal
material containing these genes into the aquatic environment is not desirable, given the possibility of
horizontal transfer of the genes to local bacterial species. Consequently, selection strategies have been
developed on the basis of the rescue of auxotrophic or phototrophic mutants with the corresponding
wild-type algal gene, or the acquisition of a resistance phenotype conferred by a dominant mutation in
the algal gene [18,48]. The final requirement is the successful expression of the introduced transgene
within the algal cell. Typically, this involves optimization of the coding sequence to match the codon
preference of the target genome (nuclear or chloroplast) in the chosen algal species, and fusion of this
coding sequence to a promoter and to 5′ and 3′ untranslated regions (UTRs) known to be functional
in the alga. Such cis elements are usually derived from endogenous genes such as those encoding
components of the photosynthetic apparatus that are known to be highly expressed in the alga.
However, plant and plant viral promoters (e.g., from maize and from Cauliflower Mosaic Virus)
have also been shown to drive transgene expression in the nucleus [18,49], and synthetic promoters
and 5′ UTRs that circumvent natural feedback regulations in the nucleus and chloroplast are being
developed as orthogonal elements for transgenesis [50,51].
To date, progress in the development of transgenic microalgae as platforms for oral delivery of
biomolecules for aquaculture disease is limited but encouraging. As detailed in Table 1, there are reports
on the production of viral antigens, antimicrobial peptides, and double-stranded RNA (dsRNA) by
nuclear and chloroplast transformations of several algal species. In one study, the feeding of Medaka
fish with Nannochloropsis oculata expressing bovine lactoferricin—a broad-spectrum antimicrobial
peptide that can kill or inactivate many bacterial, viral, and fungal pathogens—six hours prior to
V. parahaemolyticus challenge showed a 70–85% survival rate compared to 5% survival rates in fish fed
with the wild-type alga [52]. In another study, Feng et al. expressed the gene for viral envelope protein
28 (VP28) from WSSV in the nucleus of D. salina under the control of the maize Ubi1 promoter and
obtained 78 µg of recombinant protein per 100 ml of culture [53]. A cell lysate from the transgenic alga
was used to coat commercial crayfish feed, and the animals were challenged with WSSV following
feeding. Whilst the control challenge experiments resulted in 100% mortality, the VP28-fed crayfish
showed significantly higher survival rates, with only 59% mortality. In a similar study, recombinant
VP28 was produced by chloroplast transformation of C. reinhardtii, and the alga was fed to shrimp
(L. vannamei) followed by challenge with WSSV. A significant rate of survival (87%) was found in shrimp
receiving the transgenic C. reinhardtii, whereas no shrimp survived in the group fed the wild-type
alga ([54], T.W. Brocklehurst, personal communication). Engineering of C. reinhardtii was also used by
Siripornadulsil et al. [55] to produce the p57 antigen of Renibacterium salmoninarum, the causative agent
of bacterial kidney disease (BKD). The researchers used two strategies: (1) chloroplast transformation
to produce the full-length p57 protein that accumulated in the organelle; (2) nuclear transformation
to produce a chimeric protein consisting of a 14-residue antigenic domain of p57 fused to a plasma
membrane protein such that the p57 antigen would be presented on the algal cell surface. Juvenile
rainbow trout fed a diet containing the dried algae or immersed in water containing the live algae
were shown to produce antibodies to the p57 antigen.
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Table 1. Genetic engineering of microalgae to produce therapeutic proteins and biomolecules against aquaculture diseases.
Species Site of TransgeneInsertion
DNA Delivery Method and




p57 secreted protein from Renibacterium
salmoninarum, the cause of bacterial kidney
disease (BKD) in salmonid fish
N.D. 1
Induction of anti-p57 antibodies in the
blood of fish fed with the dried algae [55]
Microparticle bombardment;
spectinomycin resistance
Viral envelope protein 28 (VP28) of white
spot syndrome virus (WSSV)
G-protein from infectious hematopoietic
necrosis virus (IHNV)














VapA and AcrV antigens of fish bacterial
pathogen Aeromonas salmonicida
0.3% TSP 3 (VapA)
0.8% TSP (AcrV)
Initial fish feeding trials revealed no adverse
effects of feeding, but also no
immunological response to either antigen or
protection against the pathogen (see: [57])
[58]
Agitation with glass beads;
restoration of photosynthesis VP28 of white spot syndrome virus (WSSV) N.D.
Challenge trials showed reduced mortality
from WSSV for shrimp fed with algal meal





14 amino acid antigenic domain of p57
fused to an endogenous plasma
membrane protein
N.D. Induction of anti-p57 antibodies in theblood of fish fed with the dried algae [55]
Agitation with glass beads;
paromomycin resistance
374 bp double-stranded RNA targeting
RdRp gene of yellow head virus (YHV)
45 ng ds-RNA per
100 mL culture
Challenge trials showed 22% improvement
in survival rate against YHV for shrimp fed
with algal meal containing ds-RNA
[59]
Nannochloropsis oculata Nucleus Electroporation, fluorescence ofDsRed 4 reporter
Broad spectrum antimicrobial peptide
Bovine Lactoferricin (LFB) fused to DsRed N.D.
Medaka fish fed with algal meal containing
LFB showed ~85% survival against
Vibrio parahymolyticus infection compared to
control (~5%)
[52]
Dunaliella salina Nucleus Agitating with glass beads;phosphinothricin resistance VP28 of white spot syndrome virus (WSSV) 78 µg/100 mL culture
Challenge trials showed 41% survival rate
of crayfish against WSSV [53]
1 N.D.: Not Determined, 2 TCP: Total Cell Protein, 3 TSP: Total Soluble Protein, 4 DsRed: Red Fluorescence Protein.
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Whilst these and other transgenic approaches given in Table 1 focus on the production of
recombinant proteins, the production of recombinant double-stranded RNA (dsRNA) represents
a promising alternative strategy for protection against an infecting virus [60,61]. Here, the dsRNA
serves to trigger an RNA interference (RNAi) response in the animal that compromises the expression
of target viral genes. Earlier work involving oral administration of Escherichia coli expressing dsRNA
targeting shrimp viral genes resulted in a significant decrease in the viral copy number [61,62].
Subsequently, the successful integration of a hairpin DNA cassette expressing dsRNA targeting
the yellow head virus (YHV) in the C. reinhardtii nucleus has been reported [59]. A challenge test after
feeding L. vannamei shrimp with this transgenic alga demonstrated partial protection against the virus.
It is likely that the lack of full protection was in part due to the degradation of the dsRNA by RNase III
in the microalgal nucleus and that production in the chloroplast might be more effective because of the
lack of such dsRNA processing in this organelle [63].
Indeed, the use of the algal chloroplast as a platform for producing therapeutic biomolecules
is attractive for a number of reasons [44]. Firstly, as noted above, insertion of transgenes into
the chloroplast genomes is precise and predictable, with the transgene targeted to a chosen locus.
In contrast, nuclear transformation of most microalgal species results in unpredictable expression due
to the position effects associated with the random integration of the transgene and to the uncontrolled
integration of multiple transgene copies [64]. Secondly, there are no gene silencing mechanisms in
the chloroplast, unlike in the nucleus; therefore, transgene expression is stable and does not require
the maintenance of a selective pressure to ensure active expression. Thirdly, much higher levels of
transgene expression can be achieved in the chloroplast, partly due to the high ploidy of the chloroplast
genome and partly due to the use of promoter and UTRs from very highly expressed chloroplast
genes. Finally, chloroplast transformation of C. reinhardtii can be achieved on the basis of the rescue
of photosynthetic mutants carrying deletions in essential chloroplast genes such as psbA or psbH.
This allows the generation of transgenic lines free of any antibiotic resistance markers [48,65]. We are
currently exploiting this technology to produce marker-free chloroplast transformants of C. reinhardtii
expressing dsRNA from convergent promoters. Our first transformant line accumulates dsRNA from
the RdRp gene of YHV and is under development as an antiviral shrimp feed against YHV [66].
5. Challenges and Constraints in Algal Research
5.1. Further Advances in Microalgal Genetic Engineering
Significant advances have been made over the last ten years towards the development of genetic
engineering technologies for microalgae, and there are reports of successful transformation of over
30 species [18]. However, further advances are needed, particularly for those species listed in Section 2
that are already established as a safe, palatable, easily digestible, and nutritious ‘whole-cell’ feed.
A standardised ‘synthetic biology’ method of rapid DNA assembly using validated genetic parts need
to be combined with efficient methods of DNA delivery into the algal genome in order to accelerate
the process of designing and evaluating bespoke algal strains [67]. Furthermore, there is a need to
address concerns surrounding the use of bacterial antibiotic resistance genes as selectable markers by
developing markers based on endogenous algal genes. For those species for which the isolation of
auxotrophic mutants is possible (i.e., those with a haploid genome or those with an established sexual
cycle allowing the generation of homozygous recessive lines), the corresponding wild-type gene can
be used for selection. Conversely, endogenous genes carrying a dominant mutation can be used as
markers to transform wild-type cells, irrespective of their ploidy [68]. There is also a need to establish
generic techniques for targeted insertion of transgenes into the microalgal nuclear genome based on
the emerging CRISPR-Cas technology [48]. This would allow predictive and reproducible insertion of
transgenes into loci identified as ‘safe harbours’ for stable, high-level expression [18]. Encouraging
progress in this regard has been made by several groups who have developed facile CRISPR-Cas
techniques for green algae and diatoms [69,70]. Alternatively, integration of transgenes into the
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nuclear chromosomes can be circumvented completely by the maintenance of the genes on stable
episomal plasmids, as has been demonstrated for diatoms [70,71]. Other issues include: (1) the need to
develop more advanced algorithms for codon optimization of synthetic transgenes for each particular
microalgal species to ensure maximal translational efficiency [72,73]; (2) the need to develop promoter
systems that are easily inducible in an industrial cultivation process [74,75]. Currently, most algal
transgenics involves the use of constitutive promoters such that the recombinant product is synthesized
during algal biomass production. This can negatively impact growth, either because of the extra
metabolic burden or because of a toxic effect on the cell, and a better strategy is to induce product
synthesis towards the end of the growth phase. Tightly regulated promoters with a large dynamic
range, together with effective codon optimisation, would therefore help to achieve the highest cellular
yield of the desired product.
Finally, there is a pressing need to develop chloroplast transformation methods for the key
microalgal species for the many reasons discussed above. C. reinhardtii is the only microalgal species
for which chloroplast transformation is currently well-established, although there are isolated reports
of transformation of several other species including D. tertiolecta and P. tricornutum [44]. Nevertheless,
there have been several reports that highlighted the potential of using chloroplast engineering to
create bespoke strains as functional feed additives. For example, Stoffels et al. [76] produced highly
active anti-bacterial enzymes in the chloroplast. These lytic enzymes (termed ‘endolysins’) are derived
from bacteriophages and are highly specific for the bacterial host of the phage, in this particular case,
Streptococcus pneumoniae. It is therefore feasible that similar microalgal strains could be created that
produce one or more endolysins targeting bacterial pathogens of shrimp or fish [77]. Oral delivery of
the algae could help protect the animal against the pathogens without affecting the natural microbiome.
In a separate report, the same group showed that active human growth hormone could be produced in
the C. reinhardtii chloroplast [78]. One could therefore imagine adding fish growth hormone (fGH) to
the suite of recombinant products produced in the algal feed in order to boost fish growth. A precedent
for oral delivery of fGH was established by two separate studies [78,79] in which tilapia larvae were
fed with N. oculata engineered to produced fGH [78], and flounder fry were fed on similarly engineered
Chlorella ellipsoidea [79]. In both cases, there was a significant increase in body weight when compared to
control feedings with the non-transformed alga. Further precedents for oral delivery of other bioactives
such as antiviral agents can be found in studies using alternative platforms, such as edible plants or
microbes. This work can form the basis of future studies in which the agents are produced in the
microalgal chloroplast. For example, feeding of rock bream fish with transgenic rice callus producing
the major capsid protein of Iridovirus induced antibodies and protected the fish against the virus [80].
In a separate study, oral delivery of yeast expressing the viral capsid protein of infectious pancreatic
necrosis virus induced a specific immune response and a reduced viral load in rainbow trout [81].
5.2. Large-Scale Production and Downstream Processing
A significant challenge in the commercial exploitation of algae for aquaculture is efficient
large-scale production at a sufficiently low cost. Natural strains of algae can be cultivated outdoors
in open ponds or in closed systems such as tubular or flat-panel photobioreactors, although biomass
production costs are still high for an animal feed ingredient—in the range of 5–13 $/kg [82,83].
For production of genetically engineered algae, stricter regulations would require indoor cultivation
under artificial lighting in a closed and contained system, thereby adding significantly to the costs.
One practical solution is to reduce the capital costs (and the costs of skilled staff) by using a simple
“hanging bag” system in which the algae is grown in sterile, single-use polythene tubing [18].
Each bag typically contains 30–40 L of culture and is mixed and carbonated through bubbling with
an air/CO2 mix. With such a modular system, scaling is straightforward, as is the management of
contamination within individual bags. Harvesting of the microalgae from the bulk medium is also
a challenge given that the algal biomass represents only a few percent of the volume. Centrifugation
or microfiltration methods are expensive and generally impractical, and a better strategy is to first
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concentrate the biomass by flocculation. A suitable and cheap flocculant is chitosan, since it is
a natural byproduct of the crab industry, is already approved as a food additive, and is highly effective
as a microalgal flocculant [84]. Finally, preservation of the algal biomass can be achieved either
by freeze-drying (i.e., cryopreservation) or spray-drying [85]. Numerous studies have shown that
recombinant therapeutic proteins produced in microalgae retain bioactivity following freeze-drying,
and several studies have reported that the activity can remain stable for many months when the
dried algal powder is stored at room temperature [44]. Drying, therefore, offers a simple method
of bio-encapsulation and storage that avoids the need for a cold chain. However, this would need
to be confirmed and optimised for each recombinant product [86], and it is noteworthy that there is
one report where an algal vaccine was effective in eliciting an immune response in rabbit only when
administered as a live feed, not as a dried feed [52].
5.3. Regulation, Risk, and Public Acceptance
Although this article highlights the potential of using microalgae to control aquaculture disease, it is
important to consider also the issues and risks associated with such technology. Firstly, the commercial
cultivation of an algal species may be subject to country-specific regulations if the species is considered
non-native. Two considerations arise: (i) the import of a species might be regulated by the Nagoya
Protocol on ownership and sharing of biological resources [87] if it has been isolated recently
from another country; (ii) cultivation of an alien species might pose a significant ecological risk
through accidental escape into the environment, and therefore should be subjected to appropriate
risk assessment and approval [86]. For genetically modified microalgae, additional regulations and
risk assessments would clearly apply [88,89]. Once cultivated, the algal biomass then needs to be
treated to ensure that no viable cells survive prior to its formulation into feed and deliberate release
into the aquatic environment. Drying might be sufficient to kill all the algal cells, however it is
important to appreciate that certain species are able to form highly resistant spores under conditions
of stress (e.g., H. pluvialis) or form similarly resistant zygospores as a result of homothallic mating
(e.g., Chlamydomonas monoica). Such spores could survive the formulation process and then germinate
when exposed to the nutrient-rich conditions of the fish ponds. A further consideration in this regard
is the observation that some algal species appear able to serve as viral vectors, spreading a virus
amongst the animal population. In one report, the spread of white spot syndrome virus amongst
kuruma shrimp (Marsupenaeus japonicus) by various microalgal species was demonstrated, including
species such as Chorella sp. and D. salina species that are already used in aquaculture feeds [90]. Finally,
the horizontal transfer of transgenes from the algal biomass to environmental microorganisms (even if
the algae are killed and dried, the DNA carrying a transgene can remain intact) represents a further risk,
particularly if the algal material contains a marker gene based on bacterial antibiotic-resistance [91].
It is therefore vital that genetic engineers incorporate biocontainment strategies into transgenic lines,
both at the organism level, by creating mutant strains that would fail to grow or compete in the
natural environment (e.g., auxotrophic or mating-defective mutations [88]), and at the transgene level,
by avoiding antibiotic-based selectable markers and incorporating functional safeguards into the
transgene itself (e.g., the use of an orthogonal stop codon/tRNA system that allows the functioning of
the gene only in the algal host [92]).
Public acceptance of products from aquaculture animals that have been reared using genetically
modified (GM) feed ingredients is also a significant consideration. This is especially relevant if the
product is being marketed as ‘healthy’ and ‘sustainable’, in which case, a “GM-free” certification might
have more value to the company than the benefits afforded by a GM-based functional feed. In the
same way that the meat industry is faced with the issue of public acceptance of animal feed derived
from GM crops [93], the aquaculture industry will have to gauge the risks and benefits of adopting GM
algae. Nevertheless, we are starting to see the emergence of algal biotechnology companies exploring
the ‘functionalised algae’ space. Two examples are the Israeli company Transalgae Ltd. (Rehovot,
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Israel) and the Irish company MicroSynbiotiX Ltd. (Cork City, Ireland), both of which are developing
algal-based oral vaccines for aquaculture.
6. Conclusions
Microalgae have been shown to have potential to improve aquaculture production. The nutritional
benefits of using microalgae as a source of proteins, lipids, and essential micronutrients in the feed
are proven and are now being applied at the farm scale. Microalgae also offer opportunities for
natural protection against microbial pathogens and, hence, disease prevention through the production
of natural anti-microbial compounds and immunostimulants. Given that there are more than
10,000 species of freshwater and marine microalgae identified to date, but only a tiny percentage
have been screened for such compounds, there is clearly a rich untapped resource for such bioactives.
Furthermore, the rapidly developing field of algal genetic engineering and synthetic biology opens the
door to designer strains that can serve as functional feed additives, supplying both natural nutrition
and a suite of beneficial recombinants for both disease prevention and improved growth. Responsible
adoption of this emerging biotechnology will help contribute to a sustainable aquaculture industry
and the promotion of global food security.
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